News & Analysis on Contract Research, Manufacturing & Clinical Trials
DCAT WEEK '17
Catalent: $1bn over the past 5 years
By Melissa Fassbender
- Last updated on
As previously reported, Catalent recently acquired Acuccaps and Pharmatek to “provide additional breadth” to its portfolio, Elliot Berger, VIP Global Strategy said.
“We believe the industry … has a few challenges bringing enough good products to market fast enough, and doing it at a cost that will yield itself to a value equation acceptable to payers and industry,” he added.
“Part of the problem is in the drug development process where it takes a long time to get the molecule through the process,” he added. “We believe that no molecule should die in the process for the lack of formulation options.”
To overcome these challenges, Berger said there are a large number of proven integrated drug delivery technologies available.
Over the past 5 years, he added that Catalent has spent more than $1bn to increase its capabilities.
“What we’re trying to do is complete that set of technology … to make sure we [are meeting] the needs of the more complicated, sophisticated pipeline,” he said.
With its recent acquisitions, Catalent has more than 30 sites that supply 70bn doses of more than 7,000 products to more than 1,000 customers.